Outcomes of adalimumab biosimilar ABP 501 in patients with inflammatory bowel disease: Comparison of adalimumab naïve and switching from originator
Zenodo (CERN European Organization for Nuclear Research)（2023）
Key words
adalimumab biosimilar abp,adalimumab naïve,inflammatory bowel disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined